Facebook
Twitter
LinkedIn
ForwardInnovative and accredited continuing medical education for today’s practicing clinicians.
CME Institute is trusted by physicians across medical specialties for premium continuing education that yields the highest educational outcomes. These ACCME-accredited activities make the latest research, novel therapies, and clinical best practices accessible and approachable for physician, NP, PA, and PharmD learners.
- Expert-led insights to improve patient outcomes
- Multi-modal courses to suit all learning styles
- Timely topics for relevant application to practice
- Razor-focused approach to innovation that includes documentary-style video and micro-learning Tweetorials
- A commitment to collective mindfulness
Recent courses
Program IntroductionMood disorders throughout women's reproductive stages require comprehensive care to alleviate unnecessary suffering, comorbidities, and unwanted outcomes.
|
New biomarker technology and advancements in treatment options can lead to earlier diagnosis of AD and initiation of appropriate disease modifying therapies.
|
What is the future of schizophrenia treatment? An in-depth exploration of novel, non-dopaminergic therapies transforming the standard of care for patients with schizophrenia’s positive and negative symptoms.
|
Early diagnosis of PPD is critical for mother-infant outcomes, and new hypotheses in its pathophysiology has led to novel and emerging therapies that can improve these outcomes.
|
Diagnosis and tailored treatment of menstrual cycle- and menopausal-related mood disorders are key factors in helping women live the lives they want to live.
|
A detailed, modern digest of key advances in the diagnosis, treatment, and management of patients with Duchenne muscular dystrophy.
|
Experts discuss appropriate treatment sequencing for patients with schizophrenia, including early use of LAIs and switching from an oral antipsychotic.
|
Experts compare data on hospitalization, adherence, relapse risk, tolerance and efficacy between LAIs and OAs in the treatment of schizophrenia.
|
An updated review of pathophysiology, emerging treatments, and supportive care strategies in the cognitive dimension of Huntington disease.
|
In treating agitation in bipolar disorder/schizophrenia in the emergency department, consider efficacy and safety of therapies as well as the safety of patient and staff.
|
Management for Parkinson's disease psychosis (PDP) includes evaluating triggers, non-Parkinson's drugs, Parkinson's drugs that may contribute to symptoms, behavioral interventions, and multidisciplinary collaboration between health providers.
|
Parkinson’s disease psychosis (PDP) is a nonmotor symptom of Parkinson’s disease (PD) and includes at least 1 symptom of hallucinations, illusions, delusions, or false sense of presence after onset of PD and recurrent/continuous for 1 month or more.
|
Pages
My Courses
Please login or create an account to view your activities.
Transcript
Please login or create an account to view your activities.